ROBERT HALL: Open Payments
NPI 1184484834 · NAPLES, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,056 in 57 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $334 · 2025 $2,056
Food & beverage: $2,056
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $773 |
| AstraZeneca Pharmaceuticals LP | 6 | $428 |
| GlaxoSmithKline, LLC. | 5 | $207 |
| Phathom Pharmaceuticals, Inc. | 6 | $182 |
| Boston Scientific Corporation | 1 | $149 |
| Esperion Therapeutics, Inc. | 4 | $84 |
| Amgen Inc. | 3 | $52 |
| PFIZER INC. | 3 | $51 |
| Lilly USA, LLC | 1 | $28 |
| Novo Nordisk Inc | 1 | $27 |
Products named: QULIPTA, VRAYLAR, VOQUEZNA, FARXIGA, Intracept, BREZTRI, AIRSUPRA, AREXVY.
Industry payments across FL — which companies pay providers there.
